Bluebird Bio

bluebird bio is a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. The company's clinical programs in severe genetic diseases include its LentiGlobin? product candidate as a treatment for transfusion-dependent ß-thalassemia, and severe sickle cell disease, or severe SCD, and its Lenti-D? product candidate as a treatment for cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. bb2121 and bb21217, the company's primary product candidates in oncology, are CAR T cell product candidates for the treatment of multiple myeloma.
  • TickerBLUE
  • ISINUS09609G1004
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Roundup for Covered Companies

2 directors sold after exercising options/sold

Two Directors at Bluebird Bio Inc sold after exercising options/sold 1,861 shares at between 127.604USD and 128.605USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity ...

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

MarketLine Department

CRISPR Therapeutics - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's CRISPR Therapeutics Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by CRISPR Therapeutics since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. ...

MarketLine Department

Sorrento Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Sorrento Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Sorrento Therapeutics, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch